Regulation of insulin-like growth factor II P3 promoter by p53: A potential mechanism for tumorigenesis

Cancer Research

Volumn 56, Issue 6, 1996, Pages 1367-1373

  Zhang, Lijuan ^a   Kashanchi, Fatah ^a   Zhan, Qimin ^a   Zhan, Shili ^a   Brady, John N ^a   Fornace, Albert J ^a   Seth, Prem ^a   Helman, Lee J ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Pediatric Oncology Branch   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; MESSENGER RNA; PROTEIN P53; SOMATOMEDIN B;

ARTICLE; CARCINOGENESIS; CHROMOSOME 11P; ENZYME INHIBITION; GENE EXPRESSION; GENE LOCATION; GENE MAPPING; GENETIC TRANSFECTION; GROWTH REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR UPREGULATION; RHABDOMYOSARCOMA; TATA BOX;

GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENETIC VECTORS; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LEIOMYOSARCOMA; LUCIFERASES; MUTATION; PAPILLOMAVIRIDAE; PROMOTER REGIONS (GENETICS); RHABDOMYOSARCOMA; TATA BOX; TRANSFECTION; TUMOR CELLS, CULTURED; UP-REGULATION; VIRAL PROTEINS;

EID: 0029881592     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Van Dijk, M. A., van Schaik, F. M. A., Bootsma, H. J., Holthuizen, P., and Sussenbach, J. S. Initial characterization of the four promoters of the human insulin-like growth factor II gene Mol. Cell. Endocrinol , 81: 81-94, 1991
2. De Pagter-Holthuizen, P., Jansen, M., Van der Kammen, R. A , Van Schaik, F. M. A., and Sussenbach, J. S. Differential expression of the human insulin-like growth factor II gene: characterization of the IGF-II mRNAs and an mRNA encoding a putative IGF-II-associated protein Biochim. Biophys Acta, 950: 282-295, 1988.
3. Holthuizen, P. Van der Lee, F. M., Ikejiri, K., Yamamoto, M., and Sussenbach, J. S. Identification and initial characterization of a fourth leader exon and promoter of the human IGF-II gene. Biochim. Biophys Acta, 1087: 341-343, 1990.
4. Scott, J., Cowell, J., Robertson, M. E , Priestley, L. M., Wadey, R., Hopkins, B., Pritchard, J., Bell, G I., Rall, L. B., Graham, C. F., and Knott, T. J. Insulin-like growth factor-II gene expression in Wilms' tumor and embryonic tissues. Nature (Lond.), 317: 260-262, 1985.
5. Sussenbach, J. S. The gene structure of the insulin-like growth factor family. Growth Factor Res , 1: 33-48, 1989.
6. Jansen, M., Holthuizen, P., Van Dijk, M A., Van Schaik, F. M. A , Van den Brande, J. L., and Sussenbach, J. S Structure and expression of the insulin-like growth factor II (IGF-II) gene. In: V R. Sara, K. Hall, and H. Low (eds.), Growth Factors: From Genes to Clinical Application, pp. 25-40. New York: Raven Press, 1990.
7. Minniti, C P , Tsokos, M., Newton, W. A., Jr., and Helman, L. J. Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells. Am J. Clin. Pathol., 101: 198-203, 1994.
8. Gloudemans, T., Prinsen, I., Van Unnik, J. A M., Lips, C. J. M., Den Otter, W , and Sussenbach, J S. Insulin-like growth factor gene expression in human smooth muscle tumors. Cancer Res , 50: 6689-6695, 1990.
9. Reeve, A. E., Eccles, M. R , Wilkins, R. J , Bell, G. I., and Millow, L. J. Expression of insulin-like growth factor II transcripts in Wilms' tumor Nature (Lond.), 317: 258-260, 1985.
10. Florentino, M., Grigioni, W. F., Baccarini, P., Errico, D., De Mitri, M S , Pisi, E., and Mancini, A. M. Different in situ expression of insulin-like growth factor type II in hepatocellular carcinoma: an in situ hybridization and immunohistochemical study Diagn. Mol. Pathol., 3: 59-65, 1994.
11. Tricoli, J. V., Rall, L B., Karakousis, C. P., Herrera, L., Petrelli, N. J , Bell, G I., and Shows, T. B. Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas. Cancer Res , 46: 6169-6173, 1986.
12. Lahm, H., Amstad, P., Wyniger, J., Yilmaz, A., Fischer, J. R . Schreyer, M., and Givel, J. C. Blockade of the insulin-like growth-factor-1 receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-II-mediated autocrine loop Int. J. Cancer, 58: 452-459, 1994.
13. El-Badry, O. M., Romanus, J. A., Helman, L J , Cooper, M. J., Rechler, M. M., and Israel, M. A Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. J. Clin. Invest., 84: 829-839, 1989.
14. Haselbacher, G. K., Irminger, J. C , Zapf, J., Ziegler, W. H., and Humbel, R E. Insulin-like growth factor II in human adrenal pheochromocytomas and Wilms' tumors, expression at the mRNA and protein level. Proc. Natl. Acad. Sci. USA, 84 1104-1106, 1987.
15. Daughaday, W H. The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology, 127: 1-4, 1990.
16. Nielsen, F. C., Haselbacher, G., Christiansen, J., Lake, M., Gronborg, M., and Gammeltoft, S Biosynthesis of 10 kDa and 7.5 kDa insulin-like growth factor II (EGF-II) in a human rhabdomyosarcoma cell-line. Mol. Cell Endocrinol., 93: 87-95, 1993.
17. Singh, P., Narayan, S., Guo, Y., and Chandrasekhar, Y. IGF-I and IGF-I receptor on mouse colon cancer cells. In Vitro Cell. Dev. Biol., 27: 755-758, 1991.
18. Rogler, C E , Yang, D., Rossetti, L., Donohoe, J., Alt, E., Chand, C. J., Rosenfeld, R., Neely, K., and Hintz, R. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J. Biol. Chem., 269: 13779-13784, 1994
19. Vogelstein, B , and Kinzler, K. W p53 function and dysfunction. Cell, 70: 523-526, 1992
20. Kastan, M. B , Onyekwere, O., Sidransky, D , Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage Cancer Res , 51: 6304-6311, 1991.
21. Kastan, M. B., Zhan, Q., El-Deiry, W S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J , Jr. A mammalian cell cycle checkpoint utilizing p53 and GADD45 is defective in ataxia telangiectasia. Cell, 71: 587-597, 1992.
22. Kuerbitz, S. J., Plunkett, B. S , Walsh, W V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl Acad Sci. USA, 89. 7491-7495, 1992
23. Tishler, R. B., Calderwood, S. K., Coleman, C. N., and Price, B. D. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res., 53. 2212-2216, 1993.
24. Zhan, Q , Carrier, F., and Fornace, A J., Jr. Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol. Cell. Biol., 13: 4242-4250, 1993.
25. Lowe, S. W., Schmitt, E M., Smith, S. W , Osborne, B. A , and Jacks, T. p53 is required for radiation induced apoptosis in mouse thymocytes. Nature (Lond.), 362 847-849, 1993.
26. Lu, X., and Lane, D. P. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Cell, 75. 765-778, 1993.
27. Zhan, Q , Fan, S., Bae, I , Guillouf, C , Liebermann, D. A , O'Connor, P. M., and Fornace, A. J., Jr. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene, 9: 3743-3751, 1994.
28. El-Deiry, W. S., Kern, S E., Pietenpol, J. A., Kinzler, K W., and Vogelstein, B. Definition of a consensus binding site for p53 Nat. Genet., 1: 45-49, 1992.
29. Funk, W D., Pak, D. T., Karas, R. H., Wright, W. E., and Shay, J. W. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol., 12: 2866-2871, 1992
30. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
31. Wu, X., Bayle, J. H , Olson, D., and Levine, A. J. The p53-mdm-2 autoregulatory feedback loop. Genes & Dev., 7: 1126-1132, 1993
32. Liu, X., Miller, C. W., Koeffler, P. H., and Berk, A. J. The p53 activation domain binds the TATA box-binding polypeptide in holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol. Cell. Biol., 13: 3291-3300, 1993.
33. Mack, D. H., Vartikar, J., Pipas, J M., and Laimins, L. A Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosomal instability syndromes. Nature (Lond.), 363: 281-283, 1993
34. Seto, E , Usheva, A., Zambetti, G. P., Momand, J., Horikoshi, N., Weinmann, R., Levine, A. J., and Shenk, T. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl Acad. Sci USA, 89: 12028-12032, 1992.
35. Borellini, F., and Glazer, R. I. Induction of SP1-p53 DNA-binding heterocomplexes during granulocyte/macrophage colony-stimulating factor-dependent proliferation in human erythroleukemia cell line TF-1. J. Biol Chem., 268: 7923-7928, 1993
36. Agoff, S. N., Hou, J., Linzer, D. I. H., and Wu, B. Regulation of the human hsp70 promoter by p53 Science (Washington DC), 259. 84-87, 1993.
37. Prives, C How loops, β sheets, and α helices help us to understand p53. Cell, 78: 543-546, 1994.
38. Katayose, D , Wersto, R., Cowan, K. H., and Seth, P. Effects of a recombinant adenovirus expressing WAF1/Cip1 on cell growth, cell cycle, and apoptosis. Cell Growth & Differ , 6: 1207-1212, 1995.
39. Katayose, D., Gudas, J., Nygeun, H , Cowan, K , and Seth, P. Cytotoxic effects of adenovirus-mediated wild type p53 expression on normal and tumor mammary epithelial cells. Clin. Cancer Res , 1: 889-898, 1995.
40. Baker, S J., Markowitz, S., Fearon, E. R., Willson, J V., and Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (Washington DC), 249: 912-915, 1990.
41. Kern, S. E., Pietenpol, J, A., Thiagalingam, S., Seymour, A., Kinder, K. W., and Vogelstein, B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (Washington DC), 256. 827-830, 1992.
42. Kessis, T D., Slebos, R. J., Nelson, W G., Kastan, M. B., Plunkett, B. S., Han, S. M , Lorincz, A. T., Hedrick, L., and Cho, K. R. Human papillomavirus 16 E6 expression disrupts the p53 mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA, 90: 3988-3992, 1993
43. Chen, C., and Okayama, H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol., 7: 2745-2752, 1987
44. El-Badry, O. M., Minniti, C. P., Kohn, E. C , Houghton, P J., Daughaday, W. J., and Helman, L. J. Insulin like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth & Differ , 1: 325-331, 1990.
45. Felix, C A , Kappel, C. C., Mitsudomi, T., Nau, M. M., Tsokos, M., Crouch, G. D., Nisen, P. D., Winick, N. J., and Helman, L. J. Frequency and diversity of p53 mutation in childhood rhabdomyosarcoma. Cancer Res., 52: 2243-2247, 1992.
46. Stratton, M. R., Moss, S., Warren, W., Patterson, H., Clark, J., Fisher, C., Fletcher, C D. M., Ball, A., Thomas, M., Gusterson, B. A., and Cooper, C. S. Mutations of the p53 gene in human soft tissue sarcoma: association with abnormalities of the RB1 gene. Oncogene, 5. 1297-1301, 1990.
47. Crook, T., Tidy, J A., and Vousden, K H. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell, 67. 547-556, 1991.
48. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J , and Howley, P M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63: 1129-1136, 1990.
49. Zawel, L., and Reinberg, D. Initiation of transcription by RNA polymerase II: a multi-step process. Prog. Nucleic Acids Res Mol. Biol., 44: 67-108, 1993.
50. Conaway, R. C., and Conaway, J. W General initiation factors for RNA polymerase II. Annu Rev. Biochem , 62. 161-190, 1993.
51. Casey, G., Lo-Hsueh, M., Lopez, M. E., Vogelstein, B., and Stanbridge, E. J. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene, 6: 1791-1797, 1991.
52. Chin, K-V., Ueda, K., Pastan, I., and Gottesman, M. M. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science (Washington DC), 255: 459-462, 1992.
53. Deb, S , Jackson, C. T., Subler, M. A., and Martin, D. W. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells J Virol., 66: 6154-6170, 1992.
54. Scheffner, M., Munger, K., Byrne, C. M., and Howley, P. M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl. Acad. Sci. USA, 88: 5523-5527, 1991.
55. Lechner, M. S., Mack, D. H., Finicle, A. B , Crook, T , Vousden, K. H., and Laimins, L A. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J., 11: 3045-3052, 1992.
56. Mietz, J. A , Unger, T., Huibregtse, J. M., and Howley, P M. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J., 11. 5013-5020, 1992.
57. Ragimov, N., Krauskopf, A., Navot, N., Rotter, V., Oren, M., and Aloni, Y. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene, 8: 1183-1193, 1993.
58. II60. Science (Washington DC), 267: 100-104, 1995.
59. Shaulian, E., Haviv, I , Shaul, Y , and Oren, M. Transcriptional repression by the C-terminal domain of p53. Oncogene, 10: 671-680, 1995.